hypoglycemia semaglutide Hypoglycaemia from GLP-1 Injections Study flags low blood sugar

During Heat Exposure Drink on a schedule rather than waiting for thirst

Rayego-Mateos, S

As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)

Read the paper here - #MASLD #MetabolicHealth #LiverDisease #CircadianRhythm #MedicalResearch #Endocrinology #Hepatology To view or add a comment, sign in Dr

No authorization